Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins
| Autor: | Kingston Mills, Page M, Wl, Chan, Kitchin P, Ej, Stott, Taffs F, Jones W, Rose J, Ling C, Silvera P |
|---|---|
| Předmět: |
Immunity
Cellular Vaccines Synthetic T-Lymphocytes Immunoblotting Vaccination Simian Acquired Immunodeficiency Syndrome Gene Products env Gene Products gag Enzyme-Linked Immunosorbent Assay Viral Vaccines Antibodies Viral Lymphocyte Activation Macaca fascicularis Vaccines Inactivated Neutralization Tests Animals Interleukin-2 Simian Immunodeficiency Virus |
| Zdroj: | Scopus-Elsevier Kingston Mills Europe PubMed Central |
| Popis: | Vaccination of cynomolgus macaques with beta-propiolactone inactivated SIVmacBK28 in Freund's adjuvant induced low but detectable levels of anti-SIV envelope (env) antibodies and T-cell responses and protected against challenge with the 32H isolate of SIVmac251 grown in C8166 cells. In contrast, purified recombinant SIV env and gag proteins derived from BK28 formulated in Syntex adjuvant generated consistent and long-lived cellular and humoral immune responses to SIV env, but failed to protect against infection with the 32H virus. Thus, protection against a heterogeneous challenge stock is possible by immunization with a molecularly-cloned virus, but not with recombinant proteins from the same molecular origin. High levels of anti-cell antibodies induced by the whole virus vaccine, but not by recombinant proteins, may have contributed to the protection observed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|